Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BI 905681

Next Previous
X
Search
Drug Profile

BI 905681

Alternative Names: BI-905681

Latest Information Update: 28 Jan 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Class Antineoplastics
  • Mechanism of Action Low density lipoprotein receptor-related protein-5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 28 Jan 2023 No recent reports of development identified for phase-I development in Solid-tumours(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV, Infusion)
  • 27 May 2021 Boehringer Ingelheim completes a phase I trial in Solid tumours (Late-stage disease, Inoperable/Unresectable, Metastatic disease Second-line therapy or greater) in USA (IV) (NCT04147247)
  • 05 Jun 2020 Boehringer Ingelheim re-initiates enrolment in a phase I trial in Solid tumours (Late-stage disease, Inoperable/Unresectable, Metastatic disease Second-line therapy or greater) in USA (IV) (NCT04147247)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top